NervGen Announces Leadership Transition to Support Strategic Growth and ExpansionChairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial ResultsJuly 17, 2025 7:30 AM EDT | Source: NervGen Pharma Corp.Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervou ...